Biohit Oyj — Share Issue/Capital Change 2016

Jun 17, 2016

Disclosure 343579

Biohit Oyj - Company Announcement

Biohit Oyj Stock Options I 2013 will be registered in the Finnish book-entry system

Biohit Oyj Stock Exchange Release June 17, 2016 at 09:30 am local time (EEST) Biohit Oyj has decided to convert all outstanding Biohit Oyj I 2013A–E stock options into Biohit Oyj I 2013 stock options. Additionally, the Board of Directors of Biohit Oyj has decided to register the Stock Options I 2013 in the Finnish book-entry system. Registration will not affect the terms of the Option Scheme or share subscription periods. Currently a total of 132,940 pcs of Stock Options I 2013 have been used for share subscription. At the time of the conversion, the number of outstanding I 2013 stock options amounts to 367,060 pcs out of which 127,060 pcs have been vested and a further 90,000 granted but not vested. Each option entitles its holder to subscribe for one new B-share in the Company. The share subscription price is currently 2.2766 euros. As a result of the exercise of the stock options I 2013, the number of the Company’s shares may increase by a maximum of 367,060 new shares. Stock Options I 2013 will not be listed on the Nasdaq Helsinki. New shares subscribed with options I 2013 will be listed on the main list of the Nasdaq Helsinki together with the Company’s existing B shares after the new shares have been registered. Shares will establish shareholders rights as of the date of share registration. Evli Bank Plc acts as a subscription place for share subscription with Company’s I 2013 options. The terms and conditions of Biohit Oyj Stock Option Plan I 2013 are available on the company’s website www.biohithealthcare.com/investors Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com